Pharmacology, Toxicology and Pharmaceutical Science
Adverse Event
6%
Bacterial Infection
6%
BCG Vaccine
25%
Chemotherapy
6%
Chronic Disease
25%
Clinical Trial
9%
Coronavirinae
25%
Cross-Sectional Study
5%
Cytokine
11%
Disease
49%
HIV
38%
Immune Deficiency
6%
Infection
100%
Inflammation
6%
Influenza Vaccine
22%
Intervention Trial
6%
Live Vaccine
13%
Messenger RNA
25%
mRNA Vaccine
6%
Mucocutaneous Lymph Node Syndrome
6%
Mycobacterium Bovis BCG
52%
Mycobacterium Tuberculosis
6%
Mycoplasma genitalium
25%
Observational Study
30%
Pandemic
92%
Placebo
53%
Prednisone
6%
Prevalence
40%
Randomized Clinical Trial
50%
Randomized Controlled Trial
78%
SARS Coronavirus
20%
Severe Acute Respiratory Syndrome
5%
Skin Manifestation
6%
Table Salt
12%
Vaccinia
15%
Vaccinia Vaccine
5%
Virus Infection
12%
Medicine and Dentistry
BCG Vaccine
25%
Clinical Trial
6%
COVID-19
64%
Cross Reaction
6%
Cumulative Incidence
7%
Disease
13%
Hazard Ratio
15%
Health Care
59%
Human Immunodeficiency Virus
32%
Immune System
38%
Immunity
5%
Immunocompetent Cell
5%
Infection
43%
Influenza Vaccination
8%
Influenza Vaccine
22%
Kawasaki Disease
6%
Live Vaccine
5%
Messenger RNA
25%
mRNA Vaccine
6%
Mycobacterium Bovis BCG
52%
Mycoplasma genitalium
25%
Placebo
28%
Prevalence
25%
Randomized Clinical Trial
25%
Randomized Controlled Trial
25%
Secretion (Process)
6%
Sequela
6%
Serositis
6%
Severe Acute Respiratory Syndrome Coronavirus 2
13%
Skin Manifestation
6%
Study Participant
10%
Table Salt
10%
Virus Infection
10%
